What is a common first-line treatment for rheumatoid arthritis?

In the management of rheumatoid arthritis, disease-modifying antirheumatic drugs (DMARDs) serve as the cornerstone of treatment. DMARDs, such as methotrexate, are crucial because they not only alleviate symptoms but also alter the underlying disease process. This distinguishes them from other classes of medications that focus mainly on symptom management without impacting disease progression.

DMARDs work by targeting the immune system to reduce inflammation and prevent joint damage, making them essential for long-term management. Starting treatment with DMARDs can significantly improve outcomes and is recommended early in the disease course to prevent irreversible joint damage.

While nonsteroidal anti-inflammatory drugs (NSAIDs) are often used to relieve pain and inflammation, they do not modify the disease course, which is why they are typically considered adjuncts rather than first-line treatment. Glucocorticoids can also provide relief for inflammation but are usually reserved for acute exacerbations or when starting DMARD therapy, due to their potential side effects with long-term use. Biologic agents are advanced therapies usually introduced after DMARDs have been tried, particularly for patients who do not respond adequately to traditional DMARDs.

Thus, initiating treatment with DMARDs is the preferred strategy for managing rheumatoid